[A contribution to the clinical manifestations of endometriosis].
Explore the source record for details and available documents.
Adenocarcinoma↗
Biomedical subjects
J Tauber
Publications and source records attributed to J Tauber.
Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis.
This multicenter, double-masked, randomized, parallel-group study compared the efficacy and safety of ketorolac tromethamine 0.5% ophthalmic solution with levocabastine 0.05% and ketorolac tromethamine vehicle in patients with seasonal allergic conjunctivitis. One drop of ketorolac, levocabastine, or vehicle was instilled in each eye four times daily for 6 weeks. In the majority of efficacy variables, ketorolac produced the greatest improvements, followed by levocabastine and vehicle. Ketorolac was significantly more effective (P < .05) than vehicle in reducing mean itching scores, palpebral hyperemia, bulbar hyperemia, and edema. Patients treated with ketorolac reported significant improvements (P < .05) in their ability to sleep and to concentrate on work, compared with those who received vehicle. No significant differences were noted among the treatment groups in safety or tolerability. Ketorolac tromethamine 0.5% ophthalmic solution instilled four times daily is effective and safe in reducing the signs and symptoms of seasonal allergic conjunctivitis.
Adolescent↗
Immunosuppressive drugs in immune and inflammatory ocular disease.
Advances in immunology, particularly ocular immunology, have been accompanied by the emergence of safer, more specific immunosuppressive drugs, notably, cyclophosphamide, chlorambucil, methotrexate, azathioprine, cyclosporine A, bromocriptine, dapsone, and colchicine. These drugs have become an important, and often essential, part of the ophthalmologist's armamentarium against inflammatory and immune-mediated ocular diseases. In order to better acquaint the ophthalmologist with the properties of the most commonly used immunosuppressive drugs, we review the literature and relate our own experience with these agents.
Autoimmune Diseases↗
Ablation zone centration after photorefractive keratectomy and its effect on visual outcome.
PURPOSE: To determine the relation between ablation zone decentration, measured by corneal topography, and visual and refractive outcome, contrast sensitivity, glare, and subjective reports of halos after photorefractive keratectomy (PRK). SETTING: Eye Foundation, University of Missouri-Kansas City School of Medicine. METHODS: This study comprised 70 eyes of 70 patients enrolled into Phase III of the clinical investigation of the VISX 20/20 excimer laser for the correction by PRK of 1.00 to 6.00 diopters of pre-existing sphere. All patients were treated with 5.0 mm ablation zones. Preoperative and postoperative corneal topography in 67 eyes was done using the EyeSys system. Ablation zone decentration was measured relative to the pupillary center at all postoperative visits as determined from the difference or change map. RESULTS: Mean distance between the ablation zone center and the pupillary center was 0.62 mm +/- 0.34 (SD) (range 0.07 to 1.67 mm). Twenty seven of 66 patients with corneal topography (40.9%) had decentrations less than 0.5 mm; decentrations in 6 eyes (9.1%) were 1.0 mm or more from the pupillary center. No correlation was observed between the magnitude of decentration and 1 year postoperative best spectacle-corrected acuity (r = -.04, P = .76), uncorrected acuity (r = -.03, P = .84), or spherical equivalent (r = -.07, P = .59); preoperative uncorrected acuity (r = .04, P = .73) or spherical equivalent (r = -.02, P = .90); or reduction in spherical equivalent (r = .02, P = .89). The magnitude of decentration was correlated with preoperative spectacle-corrected acuity (r = -.37, P = .002). There was no difference in contrast sensitivity, glare, or halos between the cases with less than 0.5 mm of decentration and those with 0.5 mm or more of decentration. CONCLUSIONS: The degree of ablation zone decentration did not affect postoperative Snellen visual acuity or contrast sensitivity.
Adult↗
Five and three year follow-up of photorefractive keratectomy for myopia of -1 to -6 diopters.
BACKGROUND: To report the 5 and 3 year results of photorefractive keratectomy for -1 to -6 D of myopia and less than 1.50 D astigmatism. METHODS: All eyes were treated with a VISX 20/20 excimer laser with an ablation diameter of 5 mm. Our initial series of 133 eyes were treated in four groups: IIA, IIB, III and III No Nitrogen and reported on previously with follow-up from 6 to 36 months. The present report extends the observation period to 3 and 5 years for 114 eyes. RESULTS: Groups IIA and IIB were followed for 5 years and Groups III and III No Nitrogen for 3 years. Group IIA achieved 77% (10 of 13 eyes) +/-1.00 D (54% within +/-0.50 D) of emmetropia with stability from 6 months and 54% (seven of 13 eyes) had visual acuity of 20/20 or better. In Group IIB, 35% (six of 17 eyes) were +/-1.00 D (18% within +/-0.50 D) of emmetropia and stable from 18 months. Two of 17 eyes (12%) had 20/20 or better visual acuity. Group III had 76% (42 of 55 eyes) within +/-1.00 D (51% within +/-0.50 D) of emmetropia with stability after 12 months; 60% (33 of 55 eyes) had 20/20 or better visual acuity. Group III No Nitrogen had 73% (11 of 15 eyes) within +/-1.00 D (60% within +/-0.50 D) of emmetropia and were stable after 6 months; 47% (seven of 15 eyes) had 20/20 or better visual acuity. There was no hyperopic refractive shift. No correlation was found between the percent of correction achieved and preoperative amount of myopia, age, or sex. CONCLUSION: Refractive stability was achieved from 6 to 12 months in most eyes; a few required 18 months to stabilize. Groups IIA and III continued to be stable; Groups HB and III No Nitrogen showed mild regression that was not statistically significant.
Adult↗